胶原蛋白单品

Search documents
“进博红利”持续释放!大健康产业供需对接提速 有品牌进入中国市场半年跻身品类前三
Mei Ri Jing Ji Xin Wen· 2025-09-04 15:52
Core Insights - The China International Import Expo (CIIE) has successfully held seven sessions, with ongoing benefits for participating companies, particularly state-owned enterprises (SOEs) [1][2] - China Resources Group has actively participated in the CIIE, achieving significant procurement agreements and expressing clear cooperation needs across various sectors [1][4] Group 1: CIIE Participation and Impact - The CIIE has become a key platform for SOEs, with their transaction intentions accounting for nearly one-fourth of the total during the past seven sessions [2] - China Resources Group has established procurement partnerships with exhibitors from 35 countries, totaling a contract value of $15.15 billion [1][2] Group 2: Business Development and Innovation - China Resources Group is focusing on full-chain cooperation needs, including R&D, supply chain, and distribution [4] - The company plans to enhance its international presence through cross-border e-commerce and strategic partnerships with global pharmaceutical firms [5] Group 3: Global Exhibitors' Confidence in China - Global exhibitors, such as Hungary's Tutti Pharma, have expressed strong confidence in the Chinese health market, with significant sales growth and product localization efforts [6][7] - New Zealand's Pacific Alpaca Group has increased its exhibition space at the CIIE, reflecting its commitment to the Chinese market [7] Group 4: Future Developments and Trends - The upcoming eighth CIIE is set to showcase innovations in medical devices and biopharmaceuticals, attracting major global pharmaceutical companies [8] - The event will focus on health products and services for the aging population, aligning with China's "Healthy China 2030" strategy [8]